FDA upgraded the approval of pembrolizumab in combination with pemetrexed and platinum chemotherapy as a first-line treatment for patients with metastatic, nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations from accelerated to regular approval.
from Latest articles from Cancer Therapy Advisor Lung Cancer https://ift.tt/2wqJ9Nh
from Latest articles from Cancer Therapy Advisor Lung Cancer https://ift.tt/2wqJ9Nh